Smith & Nephew plc 21.4% Potential Upside Indicated by Berenberg

Broker Ratings

Smith & Nephew plc using EPIC/TICKER code (LON:SN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Berenberg. Smith & Nephew plc are listed in the Health Care sector within UK Main Market. Berenberg have set a target price of 2265 GBX on its stock. This would imply the analyst believes there is now a potential upside of 21.4% from the opening price of 1865 GBX. Over the last 30 and 90 trading days the company share price has increased 135.5 points and increased 276 points respectively. The 52 week high for the stock is 1940 GBX while the year low share price is currently 1242.5 GBX.

Smith & Nephew plc has a 50 day moving average of 1,745.90 GBX and a 200 Day Moving Average share price is recorded at 1,545.63. There are currently 1,984,330,139 shares in issue with the average daily volume traded being 2,347,819. Market capitalisation for LON:SN is £16,209,871,671 GBP.

Share on:
Find more news, interviews, share price & company profile here for:

    Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.

    Smith & Nephew Plc transforming into a higher growth and more profitable business

    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.

    Smith & Nephew Q1 trading update shows revenue growth and confident outlook

    Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook.

    Smith & Nephew reports Q4 revenue of $1,458 million, up 6.4%

    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.

    Smith+Nephew to attend AAOS 2024, showcasing leading Orthopaedic solutions

    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.

      Search

      Search